|
Feb 20
|
Aptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First Cohort
|
|
Feb 18
|
Aptose Announces Reverse Share Split
|
|
Jun 14
|
Aptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid Congress
|
|
Jun 13
|
Aptose Biosciences (APTO) Upgraded to Buy: What Does It Mean for the Stock?
|
|
May 6
|
Aptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024
|
|
Jan 31
|
Aptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment Option
|
|
Jan 29
|
This Aptose Biosciences Insider Increased Their Holding In The Last Year
|
|
Nov 30
|
Aptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive Role
|
|
Nov 2
|
Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting
|
|
Oct 23
|
Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th
|
|
Aug 24
|
Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference
|